Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Cancer Res. 2014 Oct 27;74(24):7217–7228. doi: 10.1158/0008-5472.CAN-14-0505

Fig. 1. Phenotypic effect of dasatinib (Dasa) on DDR2-mutant lung SCC cell lines, H2286 and HCC366.

Fig. 1

A: Relative cell viability after dasatinib treatment. Cells were treated with dasatinib for 96 hours, followed by cell viability assessed by CellTiter-Glo assay (Promega). Representative triplicates ± SD are presented, which showed similar results at least 3 times. B: p27 expression and PARP cleavage after dasatinib treatment (0.5 μM, 24 hours). C: Cell cycle profiling after dasatinib treatment (0.5 μM, 24 hours). D: Phosphorylation of ERK and AKT after tyrosine kinase inhibitor (TKI) treatment (0.5 μM, 3 hours). Erlo: erlotinib (EGFR TKI); Criz: crizotinib (ALK TKI). Intensity of each Western blot band was quantified and relative band intensity is shown in Fig. S1.